Streamlining HTA – Joint Scientific Consultations in the EU

By João L. Carapinha

January 31, 2025

The European Commission has adopted an implementing regulation outlining the procedural rules for joint scientific consultations on medical devices and in vitro diagnostic medical devices under the Health Technology Assessment (HTA) Regulation. These consultations enable health technology developers to receive guidance from HTA bodies on the clinical evidence needed for future joint clinical assessments. The regulation, which became applicable on January 12, 2025, aims to streamline the development and assessment process for health technologies.

Joint Scientific Consultations

The regulation provides a framework for health technology developers to consult with HTA bodies. It also enables other stakeholders to obtain early advice regarding the clinical evidence required for joint clinical assessments. The implementing act details the submission process, the selection of stakeholders/experts, and cooperation with the EMA for parallel consultations. The consultations aim to optimize the generation of robust evidence for both marketing authorization and HTA assessments, particularly for areas with high unmet needs and substantial uncertainty.

The Health Technology Assessment Regulation (HTAR) was proposed by the European Commission in 2018 and formally adopted in December 2021. It aims to enhance EU/EEA cooperation on joint health technology assessments regarding relative clinical efficacy and safety. Key aspects include: i) joint clinical assessments conducted by Member States’ HTA bodies to evaluate the clinical effectiveness and safety of new health technologies, and ii) joint scientific consultations that advise technology developers on clinical study designs and evidence generation. The regulation covers clinical aspects but excludes economic evaluations, pricing, and reimbursement decisions, which remain under national jurisdiction.

Health Economics and Outcomes Research

The HTAR is expected to reduce duplication across member states, streamline regulatory and HTA advice procedures, and enable more rapid access to innovative treatments. This harmonization can lead to efficient resource use and better alignment of evidence generation with regulatory and HTA requirements. By providing clear guidelines and a single EU-level submission process for JCAs, the HTAR enhances predictability for developers. This clarity can foster innovation and investment in the health technology sector.

The regulation emphasizes the involvement of patient organizations, clinical experts, and other relevant stakeholders. This ensures that the HTA process reflects diverse experiences and needs, ultimately improving the relevance and acceptability of health technologies. The regulation seeks to improve timely and equitable access to innovative therapies across the EU, which can significantly impact health outcomes and healthcare system efficiency.

Reference url

Recent Posts

elderly care costs 2025
      

Elderly Care Costs 2025: Rising Financial Pressures in Dutch Health Services

💡 Are you prepared for the surge in elderly care costs projected for 2025?

A recent report from Zorginstituut Nederland reveals that the financial burden on the Dutch health system is set to rise significantly due to demographic shifts and increased demand for complex care. As policymakers navigate these challenges, the insights address crucial implications for health economics, reimbursement strategies, and sustainable access to care.

Don’t miss out on understanding how these trends could shape the future of healthcare. Dive into the full article for comprehensive insights!

#SyenzaNews #HealthEconomics #HealthcarePolicy #DigitalTransformation

silencing science impact
      

Silencing Science Impact: Political Interference and Global Health Consequences

🔍 Are political interventions threatening the very foundation of scientific integrity?

A recent article from the BMJ highlights alarming shifts within U.S. governance that are undermining scientific autonomy, equity in health research, and public trust. From funding cuts to the suppression of critical fields like climate science, the implications are far-reaching.

Curious about how these changes may affect the future of healthcare and innovative reimbursement? Dive into the full discussion to understand the stakes and potential solutions.

#SyenzaNews #HealthEconomics #HealthcarePolicy

AAP childhood obesity guidelines
     

Caution Advised: Conflicts in AAP Childhood Obesity Guidelines

Are childhood obesity guidelines driving us toward conflict? 🌍 The recent AAP guidelines suggest weight loss medications for children as young as eight, but undisclosed financial ties to drug manufacturers raise serious questions about credibility.

In this article, we dive into the implications of these conflicts and the evidence gaps surrounding pharmaceutical interventions in pediatric care. Transparency and trust are crucial when it comes to the health of our children—let’s explore what needs to change.

Read more to find out how these guidelines could impact families, clinicians, and healthcare policy.

#SyenzaNews #HealthcareInnovation #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.